Inflammation-driven glial alterations in the cuprizone mouse model
  probed with diffusion-weighted magnetic resonance spectroscopy at 11.7 T by Genovese, Guglielmo et al.
 1 
Inflammation-driven glial alterations in the cuprizone mouse model probed with 
diffusion-weighted magnetic resonance spectroscopy at 11.7 T 
 
Guglielmo Genovesea,b, Marco Palomboc, Mathieu D. Santina,b, Julien Valetted,e, Clémence Ligneulf, 
Marie-Stéphane Aigrotb,g, Nasteho Abdoulkadera, Dominique Languib,g, Aymeric Millecampsg, Anne 
Baron-Van Evercoorenb, Bruno Stankoffb, Stéphane Lehericya,b, Alexandra Petiet*a,b and Francesca 
Branzoli*a,b 
 
a Paris Brain Institute (Institut du Cerveau – ICM), Center for Neuroimaging Research - CENIR, F-
75013, Paris, France 
b Hopital Pitié-Salpêtrière, ICM, Sorbonne Université, Inserm U 1127, CNRS UMR 7225, F-75013, 
Paris, France 
c Centre for Medical Image Computing and Department of Computer Science, University College 
London, London, United Kingdom 
d Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), MIRCen, F-92260, 
Fontenay-aux-Roses, France  
e Neurodegenerative Diseases Laboratory, UMR9199, CEA, CNRS, Université Paris Sud, Université 
Paris-Saclay, F-92260, Fontenay-aux-Roses, France 
f Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical 
Neurosciences, University of Oxford, Oxford, United Kingdom 
g Core Facility ICM.Quant, Institut du Cerveau - ICM, Paris, France. 
 
 
 
*The authors equally contributed to the study 
 
 
 
Corresponding author: 
 
Francesca Branzoli, Ph.D. 
Institut du cerveau -  ICM 
Hôpital Pitié-Salpetrière 
47 boulevard de l’Hôpital 
CS 21414 
75646 Paris Cedex 13 
Phone number: +33 (0)1 57 27 46 46  
Email: francesca.branzoli@icm-institute.org  
 
 2 
Abstract 
Inflammation of brain tissue is a complex response of the immune system to the presence of toxic 
compounds or to cell injury, leading to a cascade of pathological processes that include glial cell 
activation. Noninvasive magnetic resonance imaging markers of glial reactivity would be very useful 
for in vivo detection and monitoring of inflammation processes in the brain, as well as for evaluating 
the efficacy of personalized treatments. Due to their specific location in glial cells, myo-inositol 
(mIns) and choline compounds (tCho) seem the best candidates for probing glial-specific intra-
cellular compartments. However, their concentrations quantified using conventional proton magnetic 
resonance spectroscopy (MRS) are not specific for inflammation. In contrast, it has been recently 
suggested that?mIns intra-cellular diffusion, measured using diffusion-weighted MRS (DW-MRS) in 
a mouse model of reactive astrocytes, could be a specific marker of astrocytic hypertrophy. In order 
to evaluate the specificity of both mIns and tCho diffusion to inflammation-driven glial alterations, 
we performed DW-MRS in the corpus callosum of cuprizone-fed mice after 6 weeks of intoxication 
and evaluated the extent of astrocytic and microglial alterations using immunohistochemistry. Both 
mIns and tCho apparent diffusion coefficients were significantly elevated in cuprizone-fed mice 
compared to control mice, while histologic evaluation confirmed the presence of severe 
inflammation. Additionally, mIns and tCho diffusion showed, respectively, strong and moderate 
correlations with histological measures of astrocytic and microglial area fractions, confirming DW-
MRS as a promising tool for specific detection of glial changes under pathological conditions.  
 
Key words 
Inflammation, glial cells, diffusion-weighted spectroscopy, myo-inositol, choline compounds, 
cuprizone model 
 
 
 
 
 3 
1. Introduction 
 
Inflammation is the immune system’s response to various pathological conditions such as the 
presence of toxic compounds, damaged cells, or pathogens, and it is a common denominator of 
several brain diseases. Brain inflammatory responses involve a cascade of complex mechanisms 
including glial cell activation and it has been suggested to have both detrimental and beneficial effects 
(Martino et al., 2002; Sochocka et al., 2017). While acute inflammatory processes are thought to 
minimize ongoing injury or infection and facilitate restoration of tissue homeostasis, chronic 
inflammation may lead to secondary injury and contribute to neurodegeneration (González and 
Pacheco, 2014; Khandelwal et al., 2011). 
Detecting inflammation processes noninvasively would be highly beneficial for planning optimal 
therapeutic strategies and for monitoring the effect of anti-inflammatory treatments in several brain 
pathologies. However, specific, noninvasive markers of glial cell response to injury are still lacking. 
While diffusion MRI methods mostly target neuro-axonal integrity (Alexander et al., 2019; Jelescu 
and Budde, 2017), proton magnetic resonance spectroscopy (1H MRS) enables the specific study of 
different cell populations, including glial cells, thanks to the cell-type specific compartmentalization 
of brain metabolites. In particular, due to the preferential location of choline compounds (tCho) and 
myo-inositol (mIns) in glial cells, increased levels of tCho and mIns have been linked to inflammation 
and gliosis, respectively (Öz et al., 2014). However, changes in tCho and mIns concentrations could 
be related to concomitant pathological mechanisms, involving variations in glial cell density and 
cellular metabolic dysfunction, and, to our knowledge, they have never been proved as specific 
markers of inflammation processes. 1H MRS has been used to monitor longitudinal glial and axonal 
changes in the corpus callosum of cuprizone (CPZ)-fed mice (Orije et al., 2015). In the CPZ mouse 
model, activated astrocytes and microglia initiate inflammatory processes within the first 2-3 weeks 
of intoxication, in response to apoptosis of oligodendrocytes and onset of demyelination (Gudi et al., 
2014; Matsushima and Morell, 2006; Remington et al., 2007). After six weeks of cuprizone treatment, 
mice usually exhibit severe demyelination associated with a significant inflammatory response 
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(Morell et al., 1998). In particular, it has been suggested that the corpus callosum is the region most 
affected by the CPZ diet (Goldberg et al., 2015; Gudi et al., 2009). Biochemical longitudinal changes 
detected using MRS in the corpus callosum of CPZ mice have been attributed to reversible 
demyelination, axonal injury, and inflammation, without specificity for either lesion (Orije et al., 
2015). Interestingly, tCho levels were reduced in CPZ mice after 6 weeks of intoxication compared 
to healthy mice and mIns levels were unchanged, while histology proved evidence of ongoing 
inflammation. 
In contrast to conventional MRS, diffusion-weighted MRS (DW-MRS) informs on cell-specific 
microstructural abnormalities by probing the motion of several metabolites in brain tissue (Nicolay 
et al., 2001; Palombo et al., 2018; Ronen and Valette, 2015). DW-MRS?has been suggested to be 
more sensitive to glial reactivity than classical MRS from both clinical and preclinical investigations. 
Specifically, tCho and mIns diffusion alterations have been linked to glial cell hypertrophy driven by 
inflammation process (Ercan et al., 2016; Ligneul et al., 2019). On the other hand, the diffusion of 
the neuronal metabolite N-acetylaspartate, co-measured with N-acetylaspartylglutamate, (tNAA) has 
been proposed as a marker of intra-axonal integrity (Wood et al., 2012). 
The main goals of this study were to validate DW-MRS markers of inflammation with histological 
markers of glial cells and to compare their utility with respect to conventional MRS measurements. 
To this aim, we performed single-voxel DW-MRS experiments in the corpus callosum of control and 
CPZ-fed mice at 11.7 T and correlated apparent diffusion coefficients (ADCs) and concentrations of 
tCho and mIns with histological markers of microglia and astrocytes derived from 
immunohistochemistry (IHC). The CPZ mouse model is a very well-characterized model of 
demyelination, which is associated with severe inflammation (Kipp et al., 2009; Skripuletz et al., 
2011). Our working hypotheses are illustrated in Figure 1. We expected that activated astrocytes and 
microglia would be reflected in significantly higher mIns and tCho diffusion in CPZ mice after 6 
weeks of intoxication compared to control mice, and that these changes would be accompanied by 
significant alterations in glial cell markers measured with IHC. In addition, based on previous DW-
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MRS findings (Ligneul et al., 2019), we hypothesized that only mIns would be massively present in 
astrocytes. We also hypothesized that the diffusivity of tNAA would be unchanged due to intact intra-
axonal compartments. In contrast, both total creatine – creatine (Cr) + phosphocreatine (PCr) – (tCr) 
diffusion and metabolite concentrations were not expected to be specific markers of any pathological 
process in the CPZ mouse model, due to the concurrent presence of other alterations related to 
demyelination, such as oligodendrocyte death and mitochondrial dysfunction, which may complicate 
the interpretation of possible changes of these markers.  Our results confirmed DW-MRS as a 
promising method to detect inflammatory-driven glial changes in pathology. 
Figure 1: Working hypotheses. Schematic drawing of the known cellular alterations in CPZ mice 
after 6-week intoxication and expected corresponding changes in MRS and DW-MRS markers (right) 
compared to control mice (left). Stronger hypotheses are highlighted with bold characters. ADC: 
apparent diffusion coefficient; CC1: adenomatous polyposis coli oligodendrocyte proteins; GFAP: 
glial fibrillary acidic protein; IBA1: adaptive molecule linking ionizing calcium 1; mIns: myo-
inositol; tCho: choline compounds; tCr : creatine + phosphocreatine ; tNAA: N-acetylaspartate + N-
acetylaspartylglutamate. 
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2. Material and methods  
2.1 Animal experiments  
All animal experiments were performed in accordance with the EU Directive 2010/63/EU for animal 
experiments and approved by the Charles Darwin's Ethical Committee for Animal Experimentation 
(#6119-2016071314309890).   
Eighteen 8-week old C57Bl/6J female mice were included in the study. Female mice were chosen 
because they are easier to breed compared to males, whereas CPZ-induced cellular changes are 
similar in males and females (Taylor et al., 2010). Eight mice were fed with 0.2% CPZ for 6 weeks, 
while 10 mice were fed with a normal chow diet and used as healthy control mice. All mice were fed 
ad libidum (Pfeifenbring et al., 2015). Animal care was provided by a veterinarian and animal 
technicians. 
This study was part of a larger multimodal MRI study (MAXIMS: Myelin and AXon Imaging 
Markers Specificity) aiming at validating, through direct comparison with histology, noninvasive 
imaging markers of inflammation and axonal degeneration in the CPZ model. The mice were 
therefore split in two groups. After the imaging session, half of them were sacrificed for electron 
microscopy (EM) assessment and the other half for IHC assessment. The MRI markers were 
correlated with EM markers, and the results were the object of an independent article (Hill et al., 
2019). Here, we present the results obtained from DW-MRS experiments, which were correlated with 
astrocyte- and microglia-specific IHC markers.  
 
2.2 Experimental procedures 
Prior to the MRI/MRS experiments, the mice were anesthetized with 4% isoflurane in a mixture of 
air (flow rate: 1 l/min) and oxygen (flow rate: 0.2 l/min) for induction.  The mice were then placed 
on a stereotaxic bed with a bite bar and two ear bars. During the experiments, the level of anesthesia 
was maintained between 1 and 1.5% to keep the animal breathing in a range of 50-70 breaths per 
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minute. The respiratory rate was continuously monitored with a respiration sensor placed under the 
animal’s abdomen and connected to a computer running the small animal respiration-monitoring 
software. The mice temperature was maintained at 37°C with regulated water flow integrated to the 
stereotaxic bed and monitored with an endorectal probe.  
 
2.3 MRI hardware 
All mice were scanned with a 117/16 Biospec horizontal magnet (Bruker, Ettlingen, Germany) 
running Paravision 6.0.1 (Bruker, Ettlingen, Germany). The scanner was equipped with a BGA-9 
gradient coil capable of reaching 752 mT/m on each axis and a quadrature surfacecCryoprobeTM 
(Bruker, Ettlingen, Germany) for both radiofrequency transmission and reception.  
 
2.4 MRI/MRS protocol 
In order to place the spectroscopic volume of interest (VOI), two-dimensional T2-weighted sagittal 
and transversal images were acquired with a multi-slice multi-echo sequence (isotropic field of view, 
16 mm; matrix size: 160 × 160; isotropic resolution, 0.1 mm; TR/TE, 1500/20 ms; total acquisition 
time, 4 min).  
DW-MRS data were acquired in a VOI of 6 × 1.5 × 3 mm3 including the body of the corpus callosum 
(Figure 2A), using a single-voxel stimulated echo (STE)-localization by adiabatic selective 
refocusing (LASER) sequence described previously (Ligneul et al., 2017). In this sequence, the 
diffusion module is disentangled from the localization module, thus yielding no cross-terms between 
diffusion and selection gradients. 
The STE block consisted of three 90° pulses (pulse length of 100 μs), with de-phasing and re-phasing 
diffusion gradients located before the second 90° pulse and after the third 90° pulse, respectively. The 
LASER block consisted of a train of six slice-selective adiabatic 180° pulses (10-kHz pulse 
bandwidth). The sequence parameters were: TE/TM = 33/60 ms, TR = 5 s, spectral width = 5 kHz and 
number of complex points = 4096. Diffusion-weighting was applied in three orthogonal directions 
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([1, 1, -0.5], [1, -0.5, 1], [-0.5, 1, 1] in the scanner coordinate system) with diffusion gradient duration 
= 3 ms, diffusion time td = 64 ms and three increasing gradient strengths resulting in the b-values b1 
= 2, b2 = 4 and b3 = 6 ms/µm2. A quasi-non-diffusion-weighted condition was also acquired with: b0 
= 0.03 ms/µm2. Thirty-two averages were collected for each diffusion-weighted condition and saved 
as individual free induction decays for further processing. Water suppression was performed using 
variable power with optimized relaxation delays (VAPOR) and outer volume suppression (Tkac et 
al., 1999). For eddy current corrections, unsuppressed water reference scans were acquired using the 
same parameters as water suppressed spectra.  
For spectral fitting, a macromolecule spectrum was acquired in a control mouse using a double 
inversion recovery (TI1 = 2200 ms, TI2 = 730 ms) STE-LASER sequence (TE = 33ms, TM = 50ms, TR 
= 4000ms), with b-value = 10 ms/µm2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Volumes of interest and DW-MRS spectra in control and CPZ mice.  
A) Location of the VOIs in the body of the corpus callosum shown on coronal and sagittal views of 
T2-weighted images acquired in one control (left) and one CPZ (right) mice. B) DW-MRS spectra 
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acquired up to b = 6 ms/µm2 in direction [-0.5, 1, 1] in one control mouse (left) and one CPZ mouse 
(right).  
mIns: myo-inositol; tCho: choline compounds ; tCr : creatine + phosphocreatine ; tNAA: N-
acetylaspartate + N-acetylaspartylglutamate. 
 
2.5 Spectral processing 
All spectra were processed with an in-house written routine in MATLAB release R2016b 
(Mathworks, Natick, MA, USA). Single spectra were first corrected for eddy currents using water 
reference scans. Zero-order phase fluctuations and frequency drifts were corrected on single averages 
before summation using an area minimization and penalty algorithm and a cross-correlation 
algorithm, respectively (de Brouwer, 2009). For each b-value and diffusion-weighted direction, 
spectra were averaged across averages and subsequently analyzed using LCModel (Provencher, 
1993) for metabolite quantification. The basis set included alanine, ascorbate, aspartate, Cr, γ-
aminobutyric acid, glucose, glycine, glutamate (Glu), glutamine, glutathione, 
glycerophosphorylcholine (GPC), mIns, lactate, N-acetylaspartate, N-acetylaspartylglutamate, 
phosphocholine (PCho), PCr, phosphorylethanolamine, scyllo-inositol, taurine (Tau), threonine and 
experimentally measured macromolecules.  
 
2.6 Metabolite diffusion and concentration measures 
The ADCs of mIns, tCho, tCr and tNAA were calculated by linear regression of the logarithm of the 
signal decay in each diffusion direction. For the four metabolites, the average diffusivity was 
computed across the three diffusion-weighted directions.  
tCr absolute concentrations were evaluated from the spectra measured at b0, scaled using the water 
reference scan acquired at the same condition. Because tCr concentrations did not change 
significantly between CPZ and control mice (data not shown), the concentrations of mIns, tCho and 
tNAA were reported relative to the tCr concentrations, in order to reduce the variability due to partial 
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volume effects and water relaxation rates.  For completeness, ADCs and concentrations of Tau and 
Glu were also evaluated (Supplementary material). 
 
2.7 Immunohistochemistry  
Just after completion of the DW-MRS data collection,  four CPZ and five control mice were sacrificed 
for IHC assessment. The animals were deeply anesthetized with a lethal dose of Euthasol (400 mg/ml, 
100 mg/kg) prior to a transcardiac perfusion with 4% paraformaldehyde (PFA). The brains were 
rapidly removed and post-fixed in 4% paraformaldehyde for 24 hours, prior to cryoprotection in a 
25% sucrose/phosphate buffer saline (PBS) solution. The brains were then frozen at -50°C using 
isopentane. Sagittal sections were cut using a cryostat with a thickness of 25 μm that were regularly 
spaced at 120-240 µm intervals.  
Only one hemisphere was used and sections were collected from 0.96 mm relative to the Bregma 
until reaching the median line (-0.04 mm from the Bregma).  Up to 40 tissue sections, of 25 μm each, 
per animal, were harvested. For analysis, 4 tissue sections at different levels from Bregma were 
selected such that they covered the same region of the brain for each animal. 
 
2.8 Immunohistochemistry data analysis 
From the IHC samples, we estimated the astrocyte (AAF), microglia (MAF) and oligodendrocyte 
area fractions (OAF) in the corpus callosum. For immunofluorescence analysis of astrogliosis, 
microgliosis and oligodendrocyte density the following antibodies were used respectively: anti-GFAP 
(polyclonal rabbit anti-glial fibrillary acidic protein, Agilent, 1:500 dilution), anti-IBA1 (rabbit anti-
adaptive molecule linking ionizing calcium 1, Sobioda, 1:500 dilution) and anti-CC1 (adenomatous 
polyposis coli oligodendrocyte proteins, Anti-APC (Ab-7) mouse mAb (CC1), Merck, 1:100 
dilution). A series consisting of ten slices were scanned with the X20 lens and Z-stacked with the 
Carl ZEISS Axio Scan.Z1 scanner. All analyses were performed in the body of the corpus callosum. 
The ImageJ software (Schneider et al., 2012) was used to quantify the cells of interest. Because the 
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irregular shape of microglia and astrocytes did not allow the establishment of a count in two 
dimensions, a measurement of area seemed more suitable. The microglial and astrocyte area 
quantification was carried out by computing the ratio of the area of the stained region to the area of 
the total selected region.  
 
2.9 Statistical analysis  
Unpaired t-tests were performed to assess differences in metabolite ADCs, metabolite relative 
concentrations, and histology markers, between CPZ and control mice. Linear Pearson correlations 
between metabolite ADCs and AAF and MAF were evaluated both intra- and inter-cohort. A p-value 
< 0.05 was considered to represent statistically significant differences or statistically significant 
correlations. All statistical analyses were performed in MATLAB. 
 
 
3. Results 
3.1 DW-MRS data quality 
 
Figure 2B shows the DW spectra acquired in the body of the corpus callosum in one control and one 
CPZ mouse at different b-values. 
The Cramér-Rao lower bounds (CRLBs) associated with tNAA and tCr quantification were lower 
than 10% for all b-values. For mIns and tCho, the CRLBs were lower than 20% for all b-values, 
except for two control mice, where the CRLBs were higher than 30% for at least one b-value. MIns 
and tCho signals were therefore excluded from further analysis for these two mice. At b0, the CRLBs 
were ~2% for tNAA and tCr, and ~6% for mIns and tCho. Figure 3 shows the signal logarithm 
attenuations for mIns, tCho, tCr and tNAA averaged across mice and directions, for both groups.  
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Figure 3: Metabolite signal attenuation. Average signal logarithm attenuation as a function of the 
b-value for mIns, tCho, tCr and tNAA in control (blue circles) and CPZ (red dots) mice. Data points 
and error bars stand for mean and standard error of the mean for each mouse group (n = 8 mice per 
group for mIns and tCho; n = 8 CPZ and 10 control mice for tCr and tNAA). Only mIns and tCho 
exhibit different diffusion behavior between the two mouse groups. 
 
3.2 Apparent diffusion coefficients 
Figure 4A shows metabolite ADCs evaluated for control and CPZ mice. The ADC of mIns was 
significantly higher in CPZ (0.130 ± 0.031 μm2/ms, p = 0.004) with respect to control mice (0.082 ± 
0.024 μm2/ms). Similarly, the ADC of tCho was significantly higher in CPZ (0.188 ± 0.041 μm2/ms, 
p = 0.017) with respect to control mice (0.120 ± 0.033 μm2/ms). The ADCs of tNAA and tCr did not 
differ significantly between the two groups, neither did the ADCs of Tau and Glu (Inline 
Supplementary Figure S1A, Table S1). Metabolite ADCs are summarized in Table 1. 
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Figure 4: Metabolite ADCs and concentrations in control and CPZ mice. Box plots of metabolite 
ADCs (A) and concentrations relative to tCr (B) measured in control (blue circles) and CPZ (red dots) 
mice. For each box the central mark indicates the median ADC and the bottom and top edges indicate 
the 25th and 75th percentiles, respectively. Asterisks indicate significant difference between control 
and CPZ mice (*p < 0.05, **p < 0.005). 
mIns: myo-inositol; tCho: choline compounds ; tCr : creatine + phosphocreatine ; tNAA: N-
acetylaspartate + N-acetylaspartylglutamate. 
 
3.3 Concentrations 
Figure 4B shows metabolite concentrations relative to tCr, evaluated for control and CPZ mice. 
tNAA/tCr was significantly lower in CPZ (0.770 ± 0.096, p = 0.007) with respect to control mice 
(0.913 ± 0.096). tCho/tCr was also significantly lower in CPZ (0.090 ± 0.020, p = 0.002) with respect 
to control mice (0.142 ± 0.035). In contrast, the concentration of mIns did not differ significantly 
between groups (Table 1). In addition, Tau/tCr was significantly higher in CPZ (1.108 ± 0.095, p = 
0.006) with respect to control mice (0.939 ± 0.110), while Glu/tCr was significantly lower in CPZ 
(0.541 ± 0.054, p = 0.003) vs. control mice (0.654 ± 0.070) (Inline Supplementary Figure S1B, Table 
S1). 
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Table 1: Mean and standard deviation of metabolite ADCs and concentrations relative to tCr 
evaluated for each mouse group. The p-values are reported in the last column.  
 
ADC  
(µm2/ms) 
  
Metabolite CPZ (n = 8) Control (n = 10) p-value 
tNAA 0.086 ± 0.023 0.085 ± 0.014 0.898 
tCr 0.089 ± 0.016 0.081 ± 0.013 0.238 
 CPZ (n = 8) Control (n = 8) 
 
tCho 0.188 ± 0.041 0.120 ± 0.033 0.017 
mIns 0.130 ± 0.031 0.082 ± 0.024 0.004 
Concentration 
 
 
CPZ (n = 8) Control (n = 10) 
 
tNAA/tCr 0.770 ± 0.096 0.913 ± 0.096 0.007 
 CPZ (n = 8) Control (n = 8) 
 
tCho/tCr 0.090 ± 0.020 0.142 ± 0.035 0.002 
mIns/tCr 0.331 ± 0.045 0.355 ± 0.044 0.294 
Bold p-values indicate statistically significant differences. 
mIns: myo-inositol; tCho: choline compounds ; tCr : creatine + phosphocreatine ; tNAA: N-
acetylaspartate + N-acetylaspartylglutamate. 
 
3.4 Correlations with immunohistochemistry markers 
Representative IHC images for astrocytic (GFAP) and microglial (IBA1) immunodetection in the 
corpus callosum of control and CPZ mice are shown in Figure 5A. AAF and MAF quantified in the 
body of the corpus callosum are reported for CPZ and control mice in Figure 5B. Significantly higher 
AAF and MAF were observed in CPZ (22.7 ± 3.8 % and 24.3 ± 5.7 % respectively, p < 0.001 for 
both) with respect to control mice (7.5 ± 1.6 % and 7.2 ± 1.5 % respectively). Also, a significant 
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lower OAF was observed in CPZ (15.7 ± 2.4 %, p = 0.003) with respect to control mice (25.3 ± 3.7 
%) (Inline Supplementary Figure S2). 
 
Figure 5: Immunohistochemistry markers of glial cells in control and CPZ mice. A) 
Immunohistochemistry images for astrocytic (GFAP) and microglial (IBA1) immunofluorescence 
obtained in the corpus callosum of one control mouse (left) and one CPZ mouse (right). Yellow 
dashed lines delimit the body of the corpus callosum, where AAF and MAF were calculated.  B) Box 
plots of AAF and MAF measured in the body of the corpus callosum of control (blue circles) and 
CPZ (red dots) mice. For each box the central mark indicates the median value and the bottom and 
top edges indicate the 25th and 75th percentiles, respectively. Asterisks indicate significant difference 
between control and CPZ mice (**p < 0.005). AAF: astrocyte area fraction; MAF: microglia area 
fraction; GFAP: glial fibrillary acidic protein; IBA1: adaptive molecule linking ionizing calcium 1. 
 
Figure 6 shows correlations between the IHC glial markers and the ADCs of mIns (6A, C) and tCho 
(6B, D). As expected, the CPZ data showed a larger spread with respect to the control data, likely 
reflecting variable inflammatory response in CPZ mice. Significant correlations were observed 
between the ADC of mIns and both AAF (Pearson correlation coefficient ρ = 0.84, p = 0.004; Figure 
6A) and MAF (Pearson correlation coefficient ρ = 0.80, p = 0.009; Figure 6C). Notably, a stronger 
linear correlation was observed between the ADC of mIns and AAF (Pearson correlation coefficient 
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ρ = 0.99, p = 0.009) when considering the CPZ cohort alone (Figure 6A).  AAF and MAF were also 
significantly correlated (Pearson correlation coefficient ρ = 0.91, p < 0.001, Inline Supplementary 
Figure S3), indicating a strong interplay between astrocytic and microglia activation. 
The correlations between the ADC of tCho and both AAF (Pearson correlation coefficient ρ = 0.62, 
p = 0.077; Figure 6B) and MAF (Pearson correlation coefficient ρ = 0.61, p = 0.082; Figure 6D), 
were just above the threshold for statistical significance. No significant correlations were observed 
between the ADC of tCho and neither of the IHC glial markers when considering the CPZ group 
alone.  
No statistically significant correlations were observed between the IHC glial markers and tCr nor 
tNAA ADCs (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Correlations between DW-MRS and immunohistochemistry markers of glial cells. 
Scatter plots of AAF and MAF against mIns ADC (A, C) and tCho ADC (B, D). Only half of the 
mice were sacrificed for IHC analysis. Black lines and dashed lines indicate significant linear 
A B
C D
ADC (mIns) (μm2/ms) ADC (tCho) (μm2/ms)
ADC (mIns) (μm2/ms) ADC (tCho) (μm2/ms)
Control
CPZ
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regressions (p < 0.05) and trends (p < 0.10), respectively. Corresponding Pearson correlation 
coefficients and p-values are reported on top of each plot. In (A), the red line indicates the linear 
regression calculated considering the CPZ group alone.  The corresponding Pearson correlation 
coefficient and p-value are reported in the box.  
AAF: astrocyte area fraction; MAF: microglia area fraction; mIns: myo-inositol; tCho: choline 
compounds ; tCr : creatine + phosphocreatine ; tNAA: N-acetylaspartate + N-
acetylaspartylglutamate. 
 
 
 
 
 
 
 
4. Discussion 
 
4.1 mIns and tCho diffusion probe ongoing inflammation processes in CPZ mice 
We reported the first investigation of white matter glial cell reactivity in the CPZ mouse model using 
in vivo DW-MRS. The main finding of our study was the observation of significant alterations in the 
diffusivity of both glial metabolites under investigation, mIns and tCho, measured in the corpus 
callosum of CPZ-fed mice after 6 weeks of intoxication, and compared to control mice. The ADCs 
of mIns and tCho were significantly higher in the CPZ group, suggesting that these molecules were 
diffusing in larger intra-cellular compartments. Because mIns and tCho are known to be located 
mainly in glial cells (Choi et al., 2007; Urenjak et al., 1993), this finding was consistent with the 
presence of hypertrophic glial cells, hallmarks of ongoing inflammation, in the corpus callosum of 
CPZ mice. Despite the complexity of metabolic dynamics in the intra-cellular environment, previous 
studies have shown evidence that the fraction of metabolites confined in sub-cellular compartments 
is negligible with respect to metabolites diffusing in the cellular cytoplasm (Ligneul et al., 2017; 
Najac et al., 2016; Palombo et al., 2017, 2016; Valette et al., 2018). Thus, the metabolite displacement 
probed by DW-MRS mostly reflects the microstructure of the cells in which metabolites are 
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compartmentalized. Under our experimental conditions, (e.g. maximum b-value = 6 ms/µm2, td = 64 
ms), it was not possible to extract from the DW-MRS data quantitative morphological parameters 
such as soma radii, fiber diameters and length, however, variations in metabolite diffusion allowed to 
capture qualitative alterations in cell size.  
Our in vivo findings were corroborated by IHC data, revealing significantly higher AAF and MAF in 
the CPZ vs. the control mouse group. In addition, mIns ADC showed a significant positive correlation 
with both AAF and MAF histological markers of glial cells, when the two mouse groups were pooled 
together. Remarkably, when considering only the CPZ mouse group, the ADC of mIns showed even 
a more striking positive correlation with AAF (Figure 6A). This result was in line with a recent study 
suggesting mIns diffusion as a specific intra-cellular marker of astrocytic hypertrophy in a mouse 
model of “pure” astrocyte reactivity induced by the cytokine ciliary neurotrophic factor (CNTF) 
(Ligneul et al., 2019). Because in our study AAF and MAF were also significantly correlated (Inline 
Supplementary Figure S3), the significant correlation between mIns ADC and MAF was not 
inconsistent with the expected specificity of mIns to astrocytes. 
In the CNTF model, where the presence of hypertrophic astrocytes is not associated with neuronal 
death or with microglial activation (Escartin, 2006), Ligneul et al. (2019) reported elevated mIns 
diffusion and no significant changes in tCho diffusivity compared to control mice. In view of this 
previous report, and given our observation of a trend to a positive correlation between tCho ADC and 
MAF (Figure 6D), it is tempting to speculate that the elevated tCho diffusivity observed in our study 
in the CPZ mouse model compared to control mice may be specifically linked to microglia reactivity. 
Remarkably, our findings were very consistent with the human data obtained in patients with 
neuropsychiatric systemic lupus erythematosus (NPSLE), an inflammatory autoimmune disease 
characterized by morphological changes in microglia and astrocytes (Ercan et al., 2016). The 
differences in tCho ADC between diseased and control groups were even greater in our study, in line 
with the fact that CPZ intoxication likely induced wider and more pronounced inflammation 
compared to that observed in NPSLE patients. Nevertheless, we did not observe a significant 
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correlation between tCho ADC and MAF when considering the CPZ group alone, possibly due to the 
small number of CPZ mice examined. The hypothesis that tCho diffusion is a specific marker of 
microglia reactivity needs therefore to be corroborated by further experiments. Additionally, the tCho 
signal is generated by the contributions of GPC and PCho (while the contribution from free Cho is 
negligible in the brain). As a consequence, a change in the ratio between GPC and PCho 
concentrations, possibly associated with altered phospholipid metabolism in CPZ mice, would also 
yield a variation in tCho diffusion, due to the intrinsic different diffusivities of the GPC and PCho 
molecules.  
Notably, the unchanged diffusivity of the intra-axonal metabolite tNAA in CPZ vs. control mice, 
suggested that the intra-axonal compartments were still intact after 6 weeks of CPZ diet and under 
our experimental conditions, while glial reactivity was the dominant ongoing process in response to 
CPZ intoxication at this time point. This result was consistent with the presence of partial 
demyelination associated with still intact axonal diameters quantified using EM in the same mouse 
group and reported recently in another study (Hill et al., 2019). 
The ADC of tCr was also not significantly different between CPZ and healthy mice. Because tCr is 
located both in glia and neurons, this negative finding may reflect the concomitant presence of 
competing mechanisms that would independently lead to higher or lower tCr ADC values. In fact, 
higher tCr ADCs have been previously attributed to glial reactivity in patients with NPSLE (Ercan et 
al., 2016), while lower tCr ADC, possibly due to an increased PCr/Cr ratio, have been linked to energy 
dysregulation processes in the normal appearing white matter of patients with multiple sclerosis (MS) 
compared to healthy subjects (Bodini et al., 2018). Mitochondrial impairment has been suggested to 
significantly contribute to oligodendroglial apoptosis in CPZ-treated mice, thus compromising energy 
metabolism of cells (Pasquini et al., 2007). The combination of severe inflammation with impairment 
of energy metabolism in CPZ mice may prevent the use of tCr diffusion as a suitable marker of cell 
damage in this mouse model. 
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4.2 Metabolite concentrations are not specific markers of inflammation in CPZ mice 
We measured significantly lower tNAA/tCr, tCho/tCr and Glu/tCr and significantly higher Tau/tCr 
in CPZ vs. control mice, while no significant differences were observed in mIns/tCr concentrations 
between groups. These results were in excellent agreement with a previous MRS study conducted 
under similar experimental conditions as in our study (Orije et al., 2015). Lower tNAA/tCr and 
Glu/tCr levels may be attributed to reversible axonal suffering caused by demyelination or 
mitochondrial dysfunction induced by the CPZ diet. In contrast, the results obtained for the glial 
metabolite concentrations are difficult to interpret and cannot not be directly linked to ongoing 
inflammation. Although inflammation is known to be associated with glial cell proliferation, which 
should potentially induce an increase of both tCho and mIns levels, previous MRS studies conducted 
in patients with MS are controversial, showing elevated, reduced or unchanged tCho levels 
(Gustafsson et al., 2007; Oh et al., 2004; Sajja et al., 2009). The CPZ model is characterized by a 
failure in the energy metabolism due to mitochondrial dysfunction (Kipp et al., 2009), which could 
be the cause of tNAA, Glu and tCho reduced levels compared to control mice (Bianchi et al., 2003). 
Instead, the lack of significant differences in mIns levels between the two mouse groups was 
somehow surprising given that astrogliosis is typically associated with elevated mIns concentrations. 
The unchanged mIns concentration in CPZ vs. control mice may indicate that, after 6 weeks of CPZ 
intoxication, glial cell hypertrophy and proliferation could have been accompanied by a concomitant 
decrease in local mIns levels, which contributed to maintain apparent stable concentrations of this 
metabolite. This finding suggested that mIns concentration was not a suitable marker of glial 
reactivity, at least in this mouse model.  
Finally, the severe loss of oligodendroglial cells, corroborated by the observed lower CC1 
immunodetection in CPZ vs. control mice (Inline Supplementary Figure S2), likely contributed to the 
lower or unchanged concentrations of both the glial metabolites and tNAA (which is known to be 
present at low concentrations also in oligodendrocytes). 
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4.3 Limitations and further perspectives 
The major limitation of this study was that the AAF and MAF histological metrics evaluated the total 
area fractions occupied by astrocytes and microglia, respectively, and did not enable a distinction 
between cell size increase due to hypertrophy and increase in cell number due to cell proliferation. 
Because metabolite diffusion is known to reflect changes in cell morphology rather than proliferation, 
this may have slightly impacted the correlations between metabolite diffusion measures and 
histological metrics. 
The second major limitation of this study relied on the fact that the spectroscopic voxel included a 
non-negligible content of the grey matter surrounding the corpus callosum, possibly leading to partial 
volume effects. This could not be avoided as a smaller voxel size covering mostly the corpus callosum 
would have not enabled sufficient signal-to-noise ratio and reliable metabolite quantification at high 
b-values. Although it is known that the corpus callosum is the most affected brain area in the CPZ 
model, we cannot not exclude that inflammation may have extended to grey matter areas. If this was 
the case, we would expect a similar reactivity of glial cells as for the white matter, which may have 
further contributed to the observed abnormally high mIns and tCho ADCs. Further studies will 
include histological assessment of glial alterations also in the grey matter regions included in the 
spectroscopic voxel, as well as quantification of the glial cell number for proper estimation of both 
cell size and density variations. In addition, to further validate the role of mIns and tCho diffusion 
metrics as reliable markers of inflammation, future studies shall focus on the longitudinal variations 
of DW-MRS measures in the CPZ mouse model during different stages of de- and re-myelination. 
In addition, in order to test the hypothesis of tCho diffusion as specific marker of microglia activation, 
loss-of-function experiments in which astrocytes or microglia are selectively depleted in mice treated 
with CPZ are warranted.  
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5. Conclusions 
This study demonstrated that mIns diffusion could be used as a powerful marker of inflammation-
driven astrocytic hypertrophy in CPZ mice and suggested that tCho diffusion may be a possible 
specific probe of microglia reactivity. While mIns diffusion data showed an excellent correlation with 
histologic measures of astrocytic activation even in a very small mouse group, the validation of tCho 
diffusion data with histological markers of microglia should be corroborated in a larger cohort and 
potentially in a more specific mouse model of microglia reactivity. This work was conducted under 
experimental conditions that could be translated into the clinical setting and poses the bases for the 
study of inflammation processes in the human brain. In perspective, measuring longitudinal changes 
of DW-MRS markers of inflammation may be extremely useful for assessing disease progression, 
evaluating optimal therapeutic temporal windows, and monitoring the effect of specific treatments 
targeting inflammation. 
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Figure S1: Taurine and glutamate ADCs and concentrations in control and CPZ mice. Box plots 
of taurine and glutamate ADCs (A) and concentrations relative to tCr (B) measured in control (blue 
circles) and CPZ (red dots) mice. For each box the central mark indicates the median ADC and the 
bottom and top edges indicate the 25th and 75th percentiles, respectively. Asterisks indicate 
significant difference between control and CPZ mice (*p < 0.05, **p < 0.005). Tau: taurine; Glu: 
glutamate. 
 
 
 
 
 30 
Table 1S: Mean and standard deviation of taurine and glutamate ADCs and concentrations relative 
to tCr evaluated for each mouse group. The p-values are reported in the last column.  
 
Bold 
p-
values indicate statistically significant differences. 
Tau: taurine; Glu: glutamate. 
 
 
 
 
 
 
 
 
 
 
 
Figure S2: Immunohistochemistry oligodendrocyte markers in control and CPZ mice.  
Box plots of OAF measured in the body of the corpus callosum of control (blue circles) and CPZ (red 
dots) mice. For each box the central mark indicates the median value and the bottom and top edges 
indicate the 25th and 75th percentiles, respectively. Asterisks indicate significant difference between 
control and CPZ mice (**p < 0.005). OAF: oligodendrocyte area fraction. 
 
 
Metabolite CPZ (n = 8) Control (n = 8) p-value 
ADC 
(µm2/ms) 
Tau 0.133 ± 0.013 0.126 ± 0.012 0.268 
Glu 0.143 ± 0.027 0.127 ± 0.020 0.210 
 
 
Concentration 
 
Tau/tCr 1.108 ± 0.095 0.939 ± 0.110 0.006 
Glu/tCr 0.541 ± 0.054 0.654 ± 0.070 0.003 
 31 
 
 
 
 
 
 
 
 
 
Figure S3: Correlation between astrocytic and microglial immunohistochemistry markers. 
Scatter plots of MAF against AAF. Only half of the mice were sacrificed for IHC analysis. The black 
line indicates a significant linear regression. The corresponding Pearson correlation coefficient and 
p-value are reported on top. AAF: astrocyte area fraction; MAF: microglia area fraction. 
 
